Successful ceftolozane/tazobactam treatment of chronic pulmonary infection with pan‐resistant Pseudomonas aeruginosa

Reham Soliman; Sarah Lynch; Emma Meader; Rachel Pike; Jane F. Turton; Robert L.R. Hill; Neil Woodford; David Livermore

doi:10.1099/jmmcr.0.000025

Successful ceftolozane/tazobactam treatment of chronic pulmonary infection with pan‐resistant Pseudomonas aeruginosa

Reham Soliman, Sarah Lynch, Emma Meader, Rachel Pike, Jane F. Turton, Robert L.R. Hill, Neil Woodford, David Livermore

Research output: Contribution to journal › Article › peer-review

11 Downloads (Pure)

Abstract

The treatment of chronic Pseudomonas aeruginosa infections is challenging, with resistance and antibiogram diversity accumulating during successive therapies. Some isolates are resistant to all licensed agents, creating treatment problems and an urgent need for new therapies. Among antibiotics in advanced development, ceftolozane/tazobactam has potent in vitro antipseudomonal activity, with low MICs even for strains with AmpC β‐lactamase‐, impermeability‐ and efflux‐mediated resistance to other β‐lactams.

Original language	English
Journal	JMM Case Reports
Volume	2
Early online date	1 Apr 2015
DOIs	https://doi.org/10.1099/jmmcr.0.000025
Publication status	Published - 2015

Keywords

Pseudomonas
pan‐resistance
aeruginosa
ceftolozane‐tazobactam
bronchiectasis

Access to Document

10.1099/jmmcr.0.000025Licence: CC BY

jmmcr000025Final published version, 89.7 KBLicence: CC BY

Cite this

@article{93d31890b122444998d2665728ca6162,

title = "Successful ceftolozane/tazobactam treatment of chronic pulmonary infection with pan‐resistant Pseudomonas aeruginosa",

abstract = "The treatment of chronic Pseudomonas aeruginosa infections is challenging, with resistance and antibiogram diversity accumulating during successive therapies. Some isolates are resistant to all licensed agents, creating treatment problems and an urgent need for new therapies. Among antibiotics in advanced development, ceftolozane/tazobactam has potent in vitro antipseudomonal activity, with low MICs even for strains with AmpC β‐lactamase‐, impermeability‐ and efflux‐mediated resistance to other β‐lactams.",

keywords = " Pseudomonas, pan‐resistance, aeruginosa, ceftolozane‐tazobactam, bronchiectasis",

author = "Reham Soliman and Sarah Lynch and Emma Meader and Rachel Pike and Turton, {Jane F.} and Hill, {Robert L.R.} and Neil Woodford and David Livermore",

note = "This is an open access article published by the Society for General Microbiology under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/)",

year = "2015",

doi = "10.1099/jmmcr.0.000025",

language = "English",

volume = "2",

journal = "JMM Case Reports",

issn = "2053-3721",

publisher = "Microbiology Society",

}

TY - JOUR

T1 - Successful ceftolozane/tazobactam treatment of chronic pulmonary infection with pan‐resistant Pseudomonas aeruginosa

AU - Soliman, Reham

AU - Lynch, Sarah

AU - Meader, Emma

AU - Pike, Rachel

AU - Turton, Jane F.

AU - Hill, Robert L.R.

AU - Woodford, Neil

AU - Livermore, David

N1 - This is an open access article published by the Society for General Microbiology under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/)

PY - 2015

Y1 - 2015

N2 - The treatment of chronic Pseudomonas aeruginosa infections is challenging, with resistance and antibiogram diversity accumulating during successive therapies. Some isolates are resistant to all licensed agents, creating treatment problems and an urgent need for new therapies. Among antibiotics in advanced development, ceftolozane/tazobactam has potent in vitro antipseudomonal activity, with low MICs even for strains with AmpC β‐lactamase‐, impermeability‐ and efflux‐mediated resistance to other β‐lactams.

AB - The treatment of chronic Pseudomonas aeruginosa infections is challenging, with resistance and antibiogram diversity accumulating during successive therapies. Some isolates are resistant to all licensed agents, creating treatment problems and an urgent need for new therapies. Among antibiotics in advanced development, ceftolozane/tazobactam has potent in vitro antipseudomonal activity, with low MICs even for strains with AmpC β‐lactamase‐, impermeability‐ and efflux‐mediated resistance to other β‐lactams.

KW - Pseudomonas

KW - pan‐resistance

KW - aeruginosa

KW - ceftolozane‐tazobactam

KW - bronchiectasis

U2 - 10.1099/jmmcr.0.000025

DO - 10.1099/jmmcr.0.000025

M3 - Article

VL - 2

JO - JMM Case Reports

JF - JMM Case Reports

SN - 2053-3721

ER -